Novo Nordisk’s Ozempic wins FDA approval for chronic kidney disease
Ozempic’s Breakthrough in Chronic Kidney Disease Treatment The Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic, a GLP-1 receptor agonist, for chronic kidney disease prevention in adults with Type 2 diabetes. This means Ozempic can now be used to prevent kidney disease from worsening, reducing kidney failure, and lowering the risk of cardiovascular … Read more